Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fulcrum Therapeutics (FULC)
NASDAQ:FULC
Holding FULC?
Track your performance easily
FULC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.86 - $13.70
Previous CloseN/A
Volume345.04K
Average Volume (3M)1.01M
Market Cap
$214.68M
Enterprise Value-$25.29M
Total Cash (Recent Filing)$407.00K
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Feb 27, 2025EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding53,938,660
10 Day Avg. Volume615,539
30 Day Avg. Volume1,007,652
Standard Deviation0.51
R-Squared0.04
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.73
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.12
Enterprise Value/Revenue-0.31
Enterprise Value/Gross Profit-9.02
Enterprise Value/Ebitda1.90
Forecast
1Y Price Target
$6.50Price Target Upside63.32% Upside
Rating ConsensusHold
Number of Analyst Covering4
Fulcrum Therapeutics News
PremiumCompany Announcements
Fulcrum Therapeutics Advances Pociredir for Sickle Cell Disease
PremiumCompany Announcements
Fulcrum Therapeutics Faces Genzyme Agreement Termination
PremiumCompany Announcements
Fulcrum Therapeutics Reports Q3 2024 Financial Progress
PremiumPre-Earnings
Is FULC a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Financial Position And Business DevelopmentThe Fulcrum cash position of $273.8M leaves the door open for business development.
Muscular Dystrophy Treatment DevelopmentLosmapimod would likely be the first but potentially not the only treatment in FSHD, with competitors further behind in development.
Sickle Cell Disease Therapy DevelopmentRenewed interest in pociredir’s potential in sickle cell disease (SCD) has emerged following Pfizer’s recent withdrawal of Oxbryta from the market, which has reinvigorated investor discussions about pociredir’s opportunity in this space.
Bears Say
Clinical Trial FailureFULC announced that their lead program losmapimod did not meet its primary or secondary endpoints in its FSHD pivotal trial and the program has been discontinued.
Investor SentimentDisappointing Ph.3 REACH outcome is a significant hit to the optimism in the stock and the near-to-medium term growth prospects for the company.
Stock OutlookFulcrum's stock is expected to continue to trade closer to cash until further clarity on the pipeline is garnered.
---
Ownership Overview
Currently, No data available
---
FULC FAQ
What was Fulcrum Therapeutics’s price range in the past 12 months?
Fulcrum Therapeutics lowest stock price was $2.86 and its highest was $13.70 in the past 12 months.
What is Fulcrum Therapeutics’s market cap?
Fulcrum Therapeutics’s market cap is $214.68M.
When is Fulcrum Therapeutics’s upcoming earnings report date?
Fulcrum Therapeutics’s upcoming earnings report date is Feb 27, 2025 which is in 40 days.
How were Fulcrum Therapeutics’s earnings last quarter?
Fulcrum Therapeutics released its earnings results on Nov 13, 2024. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.396 by $0.046.
Is Fulcrum Therapeutics overvalued?
According to Wall Street analysts Fulcrum Therapeutics’s price is currently Undervalued.
Does Fulcrum Therapeutics pay dividends?
Fulcrum Therapeutics does not currently pay dividends.
What is Fulcrum Therapeutics’s EPS estimate?
Fulcrum Therapeutics’s EPS estimate is -0.28.
How many shares outstanding does Fulcrum Therapeutics have?
Fulcrum Therapeutics has 53,938,660 shares outstanding.
What happened to Fulcrum Therapeutics’s price movement after its last earnings report?
Fulcrum Therapeutics reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.396. Following the earnings report the stock price went down -2.198%.
Which hedge fund is a major shareholder of Fulcrum Therapeutics?
Among the largest hedge funds holding Fulcrum Therapeutics’s share is RA Capital Management. It holds Fulcrum Therapeutics’s shares valued at 37M.
---
Fulcrum Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.50 (63.32% Upside)
$6.50 (63.32% Upside)
Blogger Sentiment
Bullish
FULC Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.86%
12-Months-Change
Fundamentals
Return on Equity
-6.99%
Trailing 12-Months
Asset Growth
0.05%
Trailing 12-Months
Company Description
Fulcrum Therapeutics
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
---
FULC Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented some key positive developments, such as a strong financial position, progress in the pociredir program, and strategic leadership changes. However, these were balanced by significant setbacks, including the suspension of the losmapimod program and a notable workforce reduction. The financial outlook remains stable, despite zero collaboration revenue and a net loss. Overall, the call reflects a balanced sentiment with both positive and negative elements.Read More>---
FULC Stock 12 Month Forecast
Average Price Target
$6.50
▲(63.32% Upside)
Technical Analysis
Arcutis Biotherapeutics
―
Rocket Pharmaceuticals
―
Immunovant
―
Voyager Therapeutics
―
Sarepta Therapeutics
―
Alnylam Pharma
―
Best Analysts Covering FULC
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+21.88%
reiterated a buy rating 2 months ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +21.88% per trade.
---